Acumen Pharmaceuticals (ABOS) Competitors

Ovid Therapeutics (NASDAQ:OVID) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Which has more risk and volatility, OVID or ABOS?

Ovid Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500.

Do insiders and institutionals hold more shares of OVID or ABOS?

72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 13.3% of Ovid Therapeutics shares are owned by insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the media prefer OVID or ABOS?

In the previous week, Acumen Pharmaceuticals had 1 more articles in the media than Ovid Therapeutics. MarketBeat recorded 4 mentions for Acumen Pharmaceuticals and 3 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 1.54 beat Acumen Pharmaceuticals' score of 0.74 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Acumen Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Does the MarketBeat Community favor OVID or ABOS?

Ovid Therapeutics received 326 more outperform votes than Acumen Pharmaceuticals when rated by MarketBeat users. Likewise, 70.55% of users gave Ovid Therapeutics an outperform vote while only 65.52% of users gave Acumen Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Ovid Therapeutics	Outperform Votes 345 70.55%	Underperform Votes 144 29.45%
Acumen Pharmaceuticals	Outperform Votes 19 65.52%	Underperform Votes 10 34.48%

Is OVID or ABOS more profitable?

Acumen Pharmaceuticals has a net margin of 0.00% compared to Acumen Pharmaceuticals' net margin of -10,691.14%. Ovid Therapeutics' return on equity of -22.88% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-10,691.14%	-53.62%	-37.76%
Acumen Pharmaceuticals	N/A	-22.88%	-20.82%

Do analysts rate OVID or ABOS?

Ovid Therapeutics currently has a consensus price target of $8.08, suggesting a potential upside of 164.16%. Acumen Pharmaceuticals has a consensus price target of $12.00, suggesting a potential upside of 308.16%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Acumen Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has stronger valuation and earnings, OVID or ABOS?

Ovid Therapeutics has higher revenue and earnings than Acumen Pharmaceuticals. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$390K	556.61	-$52.34M	-$0.73	-4.19
Acumen Pharmaceuticals	N/A	N/A	-$52.37M	-$1.06	-2.77

Summary

Ovid Therapeutics beats Acumen Pharmaceuticals on 9 of the 17 factors compared between the two stocks.